Seres Therapeutics, Inc. (MCRB)

NASDAQ: MCRB · IEX Real-Time Price · USD
3.38
-0.03 (-0.88%)
At close: Jun 24, 2022 4:00 PM
3.45
+0.07 (2.07%)
After-hours: Jun 24, 2022 5:29 PM EDT
-0.88%
Market Cap 311.74M
Revenue (ttm) 140.70M
Net Income (ttm) -86.74M
Shares Out 92.23M
EPS (ttm) -0.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,119,262
Open 3.46
Previous Close 3.41
Day's Range 3.36 - 3.52
52-Week Range 2.50 - 25.06
Beta 3.44
Analysts Buy
Price Target 13.64 (+303.6%)
Earnings Date Aug 2, 2022

About MCRB

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infecti... [Read more...]

Industry Biotechnology
IPO Date Jun 26, 2015
CEO Eric Shaff
Employees 333
Stock Exchange NASDAQ
Ticker Symbol MCRB
Full Company Profile

Financial Performance

In 2021, MCRB's revenue was $144.93 million, an increase of 336.33% compared to the previous year's $33.22 million. Losses were -$65.58 million, -26.42% less than in 2020.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for MCRB stock is "Buy." The 12-month stock price forecast is 13.64, which is an increase of 303.55% from the latest price.

Price Target
$13.64
(303.55% upside)
Analyst Consensus: Buy
Stock Forecasts

News

What to Know About Buying Penny Stocks on June 8th

Here's what you need to know about trading on June 8th The post What to Know About Buying Penny Stocks on June 8th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: CYRNIVC

Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug

Seres Therapeutics Inc (NASDAQ: MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109 to prevent recurrent C. difficile infection (rCDI).

Seres expects its experimental C. difficile therapy to launch in the first half of 2023 if it's approved by FDA

Shares of Seres Therapeutics Inc. jumped 14.2% in premarket trading on Tuesday after the company shared data from a Phase 3 open-label study that confirmed the safety and efficacy of its experimental C....

Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced confirmatory results from ECOSPOR IV, an open-label study for SER-109, an investigational oral microbiome thera...

Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of preclinical data supporting further investigation of ...

Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Diseas...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company, today announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investi...

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infec...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at ...

Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. ...

Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (NASDAQ: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast o...

Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 Europe...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantat...

Seres Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres The...

Seres Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres The...

Seres Therapeutics (MCRB) Reports Q4 Loss, Lags Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2021 financial results and provided bus...

Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast ...

Seres Therapeutics to Present at Chardan Metagenomics and Microbiome Medicines Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres The...

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Paula Cloghessy, SPHR, SHRM-SCP, has joined Seres as Executive...

Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host a webcast investor event on Monday, January 31, 2...

Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection

Seres Therapeutics Inc (NASDAQ: MCRB) has announced the publication of data from Phase 3 ECOSPOR III study SER-109 for recurrent C. difficile infection (rCDI).

New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome T...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of da...

Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present a corporate overview at the 40th Annual J.P. M...

Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary microbiome data analyses from the Phase 2b ECO-RESET st...

Will The Rally Continue In Seres Therapeutics (MCRB) Stock After A Stellar 77% Surge In A Month?

The stock price of Seres Therapeutics, a small late stage clinical biotechnology company with a market cap of around $1 billion, is up a whopping 77% in a month, while it is up 17% over the last week. T...

Why Shares of Seres Therapeutics Rose More Than 21% on Tuesday

The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.